Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...

Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the ...

Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer "This Break Through Cancer project brings a ...

Researchers published a new study, “Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution,” in Cell that they say solves the mystery of what drives the genomic ...

Scientists at St. Jude Children’s Research Hospital report that they have identified a way to improve CAR T-cell homing for osteosarcoma. Their study “Redirecting B7-H3.CAR T cells to chemokines ...

Dialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy NEW YORK--(BUSINESS WIRE)-- OS Therapies (OSTX) (“OS ...

A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...

Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a ...

In December 2017, when I was 11, I was diagnosed with osteosarcoma, a rare bone cancer. I was one of the lucky ones—the tumor in my right femur had not spread to other parts of my body. My doctor ...